Home/Pipeline/ABI-6250

ABI-6250

Chronic Hepatitis D (HDV)

Phase 1Active

Key Facts

Indication
Chronic Hepatitis D (HDV)
Phase
Phase 1
Status
Active
Company

About Assembly Biosciences

Assembly Biosciences is a focused antiviral specialist with a mission to develop innovative therapeutics for serious viral diseases. Its strategy is validated by a major partnership with Gilead Sciences, which licensed its lead herpesvirus programs, and a clinical pipeline featuring promising candidates for HSV-2, HDV, and HBV. The company applies a targeted platform approach to discover small molecules with novel mechanisms of action, aiming to address the limitations of current standards of care.

View full company profile